BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31060715)

  • 1. PI3K pathway defects leading to immunodeficiency and immune dysregulation.
    Nunes-Santos CJ; Uzel G; Rosenzweig SD
    J Allergy Clin Immunol; 2019 May; 143(5):1676-1687. PubMed ID: 31060715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homeostatic and pathogenic roles of PI3Kδ in the human immune system.
    Sogkas G; Adriawan IR; Dubrowinskaja N; Atschekzei F; Schmidt RE
    Adv Immunol; 2020; 146():109-137. PubMed ID: 32327151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
    Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
    Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dysregulated PI3Kdelta signaling in human autoimmunity.
    Bier J; Deenick EK
    Immunol Rev; 2022 May; 307(1):134-144. PubMed ID: 35092042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
    Michalovich D; Nejentsev S
    Front Immunol; 2018; 9():369. PubMed ID: 29535736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3Kδ and primary immunodeficiencies.
    Lucas CL; Chandra A; Nejentsev S; Condliffe AM; Okkenhaug K
    Nat Rev Immunol; 2016 Nov; 16(11):702-714. PubMed ID: 27616589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
    Nguyen T; Lau A; Bier J; Cooke KC; Lenthall H; Ruiz-Diaz S; Avery DT; Brigden H; Zahra D; Sewell WA; Droney L; Okada S; Asano T; Abolhassani H; Chavoshzadeh Z; Abraham RS; Rajapakse N; Klee EW; Church JA; Williams A; Wong M; Burkhart C; Uzel G; Croucher DR; James DE; Ma CS; Brink R; Tangye SG; Deenick EK
    J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36943234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.
    Redenbaugh V; Coulter T
    Front Pediatr; 2021; 9():702872. PubMed ID: 34422726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
    Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
    Front Immunol; 2018; 9():568. PubMed ID: 29675019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
    Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
    Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
    Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
    Front Immunol; 2019; 10():77. PubMed ID: 30891027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects.
    Jhamnani RD; Nunes-Santos CJ; Bergerson J; Rosenzweig SD
    Front Immunol; 2018; 9():2172. PubMed ID: 30319630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
    Berglund LJ
    J Clin Immunol; 2023 Dec; 44(1):34. PubMed ID: 38148368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
    Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
    J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
    Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
    Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
    Yang X; Xi R; Bai J; Pan Y
    Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.